Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer

NCT00159432 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT00159432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00159432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2005
Completion date
March 31, 2013
Enrollment
63 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer